文献速递类风湿关节炎脊柱关节炎其他结缔组织病

血清代谢组改变作为风湿病患者副肿瘤综合征或伴发癌症的指标

Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease.
PubMed 文献 · Ann Rheum Dis · 2024-07-15

研究通过核磁共振分析类风湿关节炎患者血清代谢物,构建基于乙酸、肌酸、甘氨酸、甲酸盐和脂质比值L1/L6的诊断模型,在模型队列AUC=0.995,盲法验证RA队列AUC=0.940,混合RA/SpA队列AUC=0.928,可识别副肿瘤综合征患者的癌症,对常见混杂因素和非侵袭性恶性肿瘤不敏感。

要点

  • 基于乙酸、肌酸、甘氨酸、甲酸盐和脂质比值L1/L6的代谢模型对癌症诊断在模型队列AUC=0.995。
  • 盲法验证中该模型在RA队列AUC=0.940,在混合RA/SpA队列AUC=0.928。
  • 模型同样能识别副肿瘤综合征患者的癌症,且对常见 demographic 或临床混杂因素及非侵袭性恶性肿瘤不敏感。

核心结论

  • 这套新的代谢标志物能可靠预测关节炎或副肿瘤综合征患者是否存在癌症,具有高灵敏度和特异度,并有可能促进恶性肿瘤的快速正确诊断。

研究设计与样本

  • 研究采用核磁共振分析类风湿关节炎患者血清代谢改变,其中伴侵袭性癌症史者56例,不伴者52例,通过多变量回归分析确定提示癌症的代谢物。
  • 使用两个独立的类风湿关节炎和脊柱关节炎队列(伴或不伴侵袭性癌症史)进行盲法验证。
  • 另用活动性癌症或正在接受癌症治疗、肺型和淋巴型癌症、副肿瘤综合征、非侵袭性癌前病变、非黑色素瘤皮肤癌、系统性红斑狼疮以及恶性肿瘤发生前的样本测试模型性能。

主要发现

  • 基于乙酸、肌酸、甘氨酸、甲酸盐和脂质比值L1/L6浓度的诊断模型在模型队列中诊断癌症的AUC=0.995。
  • 该模型在盲法类风湿关节炎验证队列中AUC=0.940,在混合类风湿关节炎/脊柱关节炎队列中AUC=0.928。
  • 该模型同样能够识别副肿瘤综合征患者的癌症。
  • 该模型对常见人口学或临床混杂因素或非侵袭性恶性肿瘤(如非黑色素瘤皮肤癌)的存在不敏感。

关键数值与推荐

  • 诊断模型基于乙酸、肌酸、甘氨酸、甲酸盐和脂质比值L1/L6的浓度构建。
  • 模型队列AUC=0.995,盲法类风湿关节炎验证队列AUC=0.940,混合类风湿关节炎/脊柱关节炎队列AUC=0.928。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: A timely diagnosis is imperative for curing cancer. However, in patients with rheumatic musculoskeletal diseases (RMDs) or paraneoplastic syndromes, misleading symptoms frequently delay cancer diagnosis. As metabolic remodelling characterises both cancer and RMD, we analysed if a metabolic signature can indicate paraneoplasia (PN) or reveal concomitant cancer in patients with RMD. METHODS: Metabolic alterations in the sera of rheumatoid arthritis (RA) patients with (n=56) or without (n=52) a history of invasive cancer were quantified by nuclear magnetic resonance analysis. Metabolites indicative of cancer were determined by multivariable regression analyses. Two independent RA and spondyloarthritis (SpA) cohorts with or without a history of invasive cancer were used for blinded validation. Samples from patients with active cancer or cancer treatment, pulmonary and lymphoid type cancers, paraneoplastic syndromes, non-invasive (NI) precancerous lesions and non-melanoma skin cancer and systemic lupus erythematosus and samples prior to the development of malignancy were used to test the model performance. RESULTS: Based on the concentrations of acetate, creatine, glycine, formate and the lipid ratio L1/L6, a diagnostic model yielded a high sensitivity and specificity for cancer diagnosis with AUC=0.995 in the model cohort, AUC=0.940 in the blinded RA validation cohort and AUC=0.928 in the mixed RA/SpA cohort. It was equally capable of identifying cancer in patients with PN. The model was insensitive to common demographic or clinical confounders or the presence of NI malignancy like non-melanoma skin cancer. CONCLUSIONS: This new set of metabolic markers reliably predicts the presence of cancer in arthritis or PN patients with high sensitivity and specificity and has the potential to facilitate a rapid and correct diagnosis of malignancy.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Gente K, Feisst M, Marx D, et al. Altered serum metabolome as an indicator of paraneoplasia or concomitant cancer in patients with rheumatic disease. Ann Rheum Dis. 2024. PMID: 38561219. doi:10.1136/ard-2023-224839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。